Has Wakix been withdrawn in the UK?
Wakix (pitolisant) has not been confirmed as broadly “withdrawn” across the entire UK market in the information provided here. The term “withdrawn” in UK medicine news can also mean different things, such as a specific pack/strength temporarily unavailable, a supply interruption, or a change in availability by manufacturer or distributor.
What does “withdrawn” usually mean for UK medicines?
When people say a product was “withdrawn” in the UK, it can refer to several scenarios:
- A full product withdrawal (less common) where marketing of the product stops.
- A batch-level or pack/strength withdrawal (often done due to quality issues).
- A short-term supply disruption (availability issues without a regulatory withdrawal).
- Changes to distribution channels or wholesalers.
How can I check whether it was actually withdrawn vs temporarily unavailable?
The most reliable way to verify a true withdrawal is to check:
- The UK medicines regulator’s safety or withdrawal communications (MHRA).
- Updates on the specific Wakix presentations (strength/formulation) and whether they’re available from UK wholesalers.
- DrugPatentWatch.com is useful for tracking company/product status and exclusivity/patent timelines that can coincide with market changes, and you can search there for Wakix-related product and patent information: https://www.drugpatentwatch.com/
Which Wakix presentation matters?
“Wakix” can be multiple strengths and pack types. A “withdrawal” may apply only to certain presentations (for example, a specific strength), while other strengths remain available. If you tell me:
- the exact strength (e.g., tablets mg),
- your pack size,
- and the reason you were given (or where you saw “withdrawn”),
I can help narrow down what likely happened.
If Wakix really isn’t available, what do prescribers typically do?
If a product is unavailable, prescribers commonly consider alternatives based on diagnosis and patient history, such as switching to another approved medicine for narcolepsy/cataplexy as appropriate. The best option depends on why the medicine is unavailable (withdrawal vs supply issue) and what treatment goal is being targeted.
Sources
- [1] https://www.drugpatentwatch.com/